OBJECTIVES: To investigate the potential clinical, restorative, and neuroprotective effects of long-term treatment with @entity9138 in @entity191 ( @entity191 ). DESIGN: Observational open-label pilot study. SETTING: Outpatient neurologic rehabilitation clinic. @entity1 AND METHODS: Starting in June 2012, we have recruited 50 @entity1 with @entity191 (33 @entity1 and 17 @entity1 ; mean age, 70.4        12.9 years; mean disease duration, 7.3        6.7 years). All the @entity1 were assessed at baseline with the Unified @entity191 Rating Scale (UPDRS) and the @entity3777 ( @entity3777 ) and began treatment with 100   mg of @entity9138 administered intramuscularly twice a week, without any change to personal therapy. All the @entity1 were re-evaluated after 1 month and then every 3 months during treatment. RESULTS: @entity9138 treatment led to significant improvement of motor and nonmotor symptoms: mean UPDRS scores (parts I-IV) improved from 38.55        15.24 to 18.16        15.08 (p   =   2.4   *   10(-14), t test for paired data) within 3 months and remained stable over time; motor UPDRS part III score improved from 22.01        8.57 to 9.92        8.66 (p   =   3.1   *   10(-22)). Some @entity1 with a milder phenotype had complete clinical recovery. @entity3777 scores, in six @entity1 who had fatigue, improved from 53.00        8.17 to 23.60        7.77 (p   <   0.0001, t test for paired data). Follow-up duration ranged from 95 to 831 days (mean, 291.6        207.2 days). CONCLUSIONS: Administration of parenteral high-dose @entity9138 was effective in reversing @entity191 motor and nonmotor symptoms. The clinical improvement was stable over time in all the @entity1 . From our clinical evidence, we hypothesize that a dysfunction of @entity9138 -dependent metabolic processes could cause selective @entity16 in the centers typically affected by this disease and might be a fundamental molecular event provoking @entity179 . @entity9138 could have both restorative and neuroprotective action in @entity191 .

Long-Term Treatment with High-Dose XXXX in @entity191 : An Open-Label Pilot Study.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neural damage'] @entity3777 :: ('MESH:D005222', 'Disease') :: ['Fatigue Severity Scale', 'FSS'] @entity9138 :: ('MESH:D013831', 'Chemical') :: ['Thiamine', 'thiamine'] @entity191 :: ('MESH:D010300', 'Disease') :: ['Parkinson disease', "Parkinson's Disease", 'PD'] @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegeneration']
@entity9138 :: (MESH:D013831,Chemical) :: ['Thiamine']
